Abstract:figure legend Circulating noradrenaline (NA) stimulates the release of neuropeptide Y (NPY) from presynaptic sympathetic nerve terminals via activation of β‐adrenergic receptors (β‐R). This NA‐induced NPY release can be inhibited by the β‐blocker propranolol, suggesting that this mechanism, which enhances sympathoexcitation, is mediated via β‐adrenergic receptors. Cardiac disease is marked by sympathoexcitation and elevated levels of noradrenaline (NA) and cotransmitter neuropeptide Y (NPY). Increased NPY levels are associated with a greater risk of ventricular arrhythmias and mortality. Nonetheless, the factors that cause NPY release remain poorly understood. We hypothesized that circulating catecholamines might lead to NPY release from myocardial sympathetic nerve terminals via a β‐receptor‐mediated mechanism that enhances sympathoexcitation. Ventricular interstitial NA and NPY levels were measured in six Yorkshire pigs after i.v. administration of NA (1 mg) and before and after propranolol infusion (1 mg/kg). Real‐time interstitial NPY levels were measured using ventricular capacitive immunoprobes (CIs) affixed with NPY antibodies and quantified as the change in CI input current (INPY) upon binding of NPY. Interstitial NA was measured with adjacent fast‐scan cyclic voltammetry probes (INA). A left ventricular pressure catheter and continuous ECGs were used for haemodynamic recordings, and an epicardial 56‐electrode sock was used for measurements of activation recovery interval, a surrogate of action potential duration. Upon administration of NA, heart rate and left ventricular pressure increased, and activation recovery interval shortened. Notably, NA significantly increased interstitial myocardial NPY levels. After propranolol, changes in heart rate and activation recovery interval were largely mitigated. The INA increased to a similar extent post‐propranolol vs. pre‐propranolol, but changes in INPY were significantly reduced post‐propranolol. Coronary sinus plasma analyses confirmed fast‐scan cyclic voltammetry and CI findings. Hence, this study demonstrates that circulating NA induces NPY release from ventricular sympathetic nerve terminals, the mechanism for which is mediated via β‐adrenergic receptors and can be blocked by the non‐selective β‐blocker, propranolol. Key points Cardiovascular disease is characterized by sympathovagal imbalance, with increased plasma noradrenaline (NA) and neuropeptide Y (NPY) concentrations. Increased NPY levels are associated with increased ventricular arrhythmias and mortality in heart failure. Limited data are available on the specific factors that cause NPY release. In this study, fast‐scan cyclic voltammetry and capacitive immunoprobes were used to allow for real‐time in vivo measurements of interstitial myocardial neurotransmitters and neuropeptides, respectively. Using an in vivo porcine model with cardiac fast‐scan cyclic voltammetry and capacitive immunoprobes, it was shown that systemic NA can increase ventricular interstitial NPY levels, suggesting that NA induces NPY release from postganglionic sympathetic nerves. The release of NPY was blocked by administration of the non‐selective β‐blocker propranolol, suggesting that release of NPY is dependent on activation of β‐adrenergic receptors by NA.

Myocardial Beta-Adrenoceptor Down-Regulation by Norepinephrine is Linked to Reduced Norepinephrine Uptake Activity

Excessive Penile Norepinephrine Level Underlies Impaired Erectile Function in Adenosine A1 Receptor Deficient Mice

Presynaptic modulation of the norepinephrine-induced beta-adrenergic receptor desensitization phenomenon in vivo

Differential Downregulation of β1-Adrenergic Receptor Signaling in the Heart

Tonic Nmda Receptor-Mediated Inward Current In Pre-Sympathetic Pvn Neurons Is Enhanced By Heart Failure.

Evidence for reduction of norepinephrine uptake sites in the failing human heart

Nitric Oxide Regulation of Myocardial O-2 Consumption and Hep Metabolism

Circulating noradrenaline leads to release of neuropeptide Y from cardiac sympathetic nerve terminals via activation of β‐adrenergic receptors

(-)-Adrenaline elicits positive inotropic, lusitropic, and biochemical effects through beta2 -adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling

Alterations By Norepinephrine Of Cardiac Sympathetic Nerve Terminal Function And Myocardial Beta-Adrenergic Receptor Sensitivity In The Ferret - Normalization By Antioxidant Vitamins

Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure

Alterations by Norepinephrine of Cardiac Sympathetic Nerve Terminal Function and Myocardial β-Adrenergic Receptor Sensitivity in the Ferret

Renalase Deficiency In Heart Failure Model Of Rats-A Potential Mechanism Underlying Circulating Norepinephrine Accumulation

Alterations of Cardiac and Lymphocyte Β- Adrenoceptors in Rat with Chronic Heart Failure

Alterations in cardiac adrenergic terminal function and beta-adrenoceptor density in pacing-induced heart failure

Norepinephrine Induces the Raf -1 Kinase/Mitogen-Activated Protein Kinase Cascade Through Both Α 1 - and Β-Adrenoceptors

[Protein Interacting with Kinase Cα Mediates the Down-Regulation of Myocardial Norepinephrine Transporter Expression in Mice with Adriamycin-Induced Congestive Heart Failure].

The Effects of Ivabradine on Cardiac Function after Myocardial Infarction are Weaker in Diabetic Rats

β-Adrenergic Receptor Stimulation Maintains NCX-CaMKII Axis and Prevents Overactivation of IL6R-Signaling in Cardiomyocytes upon Increased Workload

Status of β1-Adrenoceptor Signal Transduction System in Cardiac Hypertrophy and Heart Failure

Propranolol therapy in experimental heart failure in rabbits improves cardiac response to catecholamines without beta-adrenoceptor up-regulation